Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Hypertrophic obstructive cardiomyopathy
0.030 Biomarker disease BEFREE Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM). 31035291 2019
Hypertrophic obstructive cardiomyopathy
0.030 GeneticVariation disease BEFREE Further, mutations of the cardiac myosin gene are the most common cause of inherited hypertrophic cardiomyopathy. 18375581 2008
Hypertrophic obstructive cardiomyopathy
0.030 GeneticVariation disease BEFREE Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. 12566107 2003